With Vioxx, researchers had been warning about the drug's possible cardiovascular risks since 2000, only a year after it was approved by the FDA.
Dr. David Graham, associate director for science in the drug safety division of the Food and Drug Administration, by early August had notified his supervisors that a study of Vioxx showed patients on the starting dose had 50 percent greater risk of cardiac arrest than those on competitor Celebrex.
The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck &amp; Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes, the chairman of the Senate Finance Committee said Thurs
